BlackBarn Capital Partners LP Purchases 31,654 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• BlackBarn Capital Partners LP increased its stake in Amneal Pharmaceuticals by 1.1%, now holding 2.88 million shares, making it the company's 4th largest position.
• Amneal Pharmaceuticals reported earnings per share of $0.23 for the last quarter, exceeding analysts' expectations of $0.17.
• Wall Street analysts maintain a consensus rating of "Buy" for Amneal Pharmaceuticals, with an average target price set at $11.60.

BlackBarn Capital Partners LP lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,881,654 shares of the company's stock after acquiring an additional 31,654 shares during the period. Amneal Pharmaceuticals accounts for about 1.5% of BlackBarn Capital Partners LP's investment portfolio, making the stock its 4th largest position. BlackBarn Capital Partners LP owned 0.93% of Amneal Pharmaceuticals worth $24,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC raised its position in shares of Amneal Pharmaceuticals by 26.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock worth $162,000 after buying an additional 4,100 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Amneal Pharmaceuticals by 53.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock worth $508,000 after purchasing an additional 21,079 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Amneal Pharmaceuticals by 45.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after purchasing an additional 99,866 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Amneal Pharmaceuticals by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after purchasing an additional 12,282 shares during the period. Finally, BNP Paribas Financial Markets increased its position in Amneal Pharmaceuticals by 209.2% during the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after purchasing an additional 113,796 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AMRX has been the topic of a number of recent research reports. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $11.60.

Insider Buying and Selling

In related news, EVP Jason B. Daly sold 22,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the transaction, the executive vice president owned 10,606 shares in the company, valued at $95,984.30. This represents a 67.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Nikita Shah sold 6,340 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $9.50, for a total transaction of $60,230.00. Following the transaction, the executive vice president owned 146,403 shares in the company, valued at $1,390,828.50. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 577,206 shares of company stock valued at $5,405,265 over the last 90 days. 17.45% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Trading Down 0.2%

AMRX traded down $0.02 during trading on Wednesday, reaching $9.36. 821,887 shares of the company were exchanged, compared to its average volume of 1,676,661. The stock has a market cap of $2.94 billion, a P/E ratio of 936.94 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 52 week low of $6.68 and a 52 week high of $9.79. The firm has a 50 day moving average of $8.43 and a 200 day moving average of $8.03.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.